NASDAQ:CDXSCodexis Stock Price, Forecast & News

Codexis' stock was trading at $10.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CDXS shares have increased by 21.5% and is now trading at $12.30. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Codexis.

Codexis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Codexis.

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.02. The biotechnology company earned $14.67 million during the quarter, compared to analyst estimates of $12.53 million. Codexis had a negative net margin of 21.40% and a negative return on equity of 14.24%. View Codexis' earnings history.

Codexis issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $78-82 million, compared to the consensus revenue estimate of $82.51 million.

2 brokerages have issued 12-month price targets for Codexis' shares. Their forecasts range from $21.00 to $21.00. On average, they expect Codexis' stock price to reach $21.00 in the next year. This suggests a possible upside of 70.7% from the stock's current price. View analysts' price targets for Codexis.

Media coverage about CDXS stock has been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Codexis earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutCodexis.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Canopy Growth (CGC), AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Antares Pharma (ATRS), Crispr Therapeutics (CRSP), Micron Technology (MU), Alibaba Group (BABA), Catalyst Pharmaceuticals (CPRX) and Enphase Energy (ENPH).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (6.93%), BlackRock Inc. (6.10%), William Blair Investment Management LLC (4.06%), Wells Fargo & Company MN (3.49%), Vivo Capital LLC (2.53%) and Janus Henderson Group PLC (2.51%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Patrick Y Yang and Thomas R Baruch. View institutional ownership trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, Wells Fargo & Company MN, JPMorgan Chase & Co., Blair William & Co. IL, Spark Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., UBS Group AG, and Morgan Stanley. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, and Thomas R Baruch. View insider buying and selling activity for Codexis.

CDXS stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, William Blair Investment Management LLC, Ziegler Capital Management LLC, Baillie Gifford & Co., Assenagon Asset Management S.A., Tarsadia Capital LLC, Aviva PLC, and Essex Investment Management Co. LLC. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang. View insider buying and selling activity for Codexis.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $12.30.

Codexis has a market capitalization of $725.92 million and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.

The official website for Codexis is www.codexis.com.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]